Related Experiment Video
Updated: Jan 7, 2026
In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
Published on: January 9, 2020
Establishment of novel stable human sinonasal NUT carcinoma cell lines
Yoko Takahashi1, Diana Bell2, Arnoldo Corona1
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Purpose:
NUT carcinoma is a rare and aggressive malignancy defined by NUTM1 gene rearrangements, with no standard treatment approaches and limited preclinical models, especially for tumors arising in the sinonasal tract. We aimed to establish and characterize novel, stable sinonasal NUT carcinoma cell lines derived from the primary disease site to contribute to therapeutic development.
Experimental Design:
Tumor specimens from a sinonasal NUT carcinoma patient were cultured to establish two cell lines, MDA-NUT87 and MDA-NUT88. Cytogenetic analysis, immunohistochemistry, RT-PCR, and Sanger sequencing confirmed the presence of the BRD4::NUTM1 fusion. Sensitivity to a BET inhibitor, OTX-015, was assessed via dose-response assays. In vivo tumorigenicity was evaluated using subcutaneous xenografts in nude mice.
Results:
MDA-NUT87 and MDA-NUT88 maintained stable morphology and harbored the characteristic t(15;19) translocation and BRD4::NUTM1 (exon 11: exon 2) fusion. The cells expressed nuclear NUT protein and responded to OTX-015 with IC50 values in the low nanomolar range. Tumorigenicity was observed in vivo, albeit with modest efficiency, suggesting a contributing role of the tumor microenvironment in disease progression.
Conclusions:
MDA-NUT87 and MDA-NUT88 are the first stable human sinonasal NUT carcinoma cell lines established from the primary tumor site. They preserve the hallmark genetic and phenotypic characteristics of NUT carcinoma and show sensitivity to BET inhibition. These models represent valuable tools for mechanistic studies and high-throughput drug screening in sinonasal NUT carcinoma.
Insights
Researchers developed new cell lines from sinonasal NUT carcinoma, a rare cancer. These models, MDA-NUT87 and MDA-NUT88, are sensitive to BET inhibitors and will aid in developing new treatments for this aggressive malignancy.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- NUT carcinoma is a rare, aggressive cancer characterized by NUTM1 gene rearrangements.
- Limited preclinical models exist, particularly for sinonasal tract tumors.
- Standard treatment approaches are lacking, necessitating new therapeutic strategies.
Purpose of the Study:
- To establish and characterize novel, stable sinonasal NUT carcinoma cell lines.
- To create valuable tools for understanding NUT carcinoma biology and developing targeted therapies.
- To facilitate preclinical research for this rare malignancy.
Main Methods:
- Establishment of two cell lines (MDA-NUT87, MDA-NUT88) from patient tumor specimens.
- Confirmation of BRD4::NUTM1 fusion via cytogenetics, immunohistochemistry, RT-PCR, and Sanger sequencing.
- Assessment of sensitivity to BET inhibitor OTX-015 and in vivo tumorigenicity studies.
Main Results:
- MDA-NUT87 and MDA-NUT88 cell lines were successfully established and maintained stable characteristics.
- The cell lines harbored the t(15;19) translocation and BRD4::NUTM1 fusion, expressing nuclear NUT protein.
- Significant sensitivity to the BET inhibitor OTX-015 was observed, with IC50 values in the low nanomolar range.
Conclusions:
- MDA-NUT87 and MDA-NUT88 are the first human sinonasal NUT carcinoma cell lines derived from primary tumors.
- These models accurately reflect the genetic and phenotypic features of NUT carcinoma.
- The cell lines demonstrate sensitivity to BET inhibition, offering a promising avenue for therapeutic development.
More Related Videos
12:04Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019